Universitätsklinikum Tübingen

Interprofessionelle Kommunikation uber,Complementary and Integrative Health" (CIH): Entwicklung und Implementierung eines Training-Programms (2022) Behzad A, Stein B, Schmitt A, Lohmuller L, Kroger B, Boltenhagen U, Joos S, et al. Conference contribution Community-level prevalence of epilepsy and of neurocysticercosis among people with epilepsy in the Balaka district of Malawi: A cross-sectional study (2022) Keller L, Stelzle D, Schmidt V, Carabin H, Reinhold AK, Keller C, Welte T, et al. Journal article Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Bluhm L, Grimmelmann I, Gutzmer R, Meier F, Garzarolli M, et al. Conference contribution Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Predictors of long-term survival of stage IV melanoma patients: a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG (2022) Placke JM, Mohr P, Bluhm L, Kahler K, Weichenthal M, Meier F, Garzarolli M, et al. Conference contribution Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution Which patients should receive adjuvant treatment - an analysis of stage IIA-IIIA patients of the CMMR (2022) Leiter-Stoppke U, Keim U, Amaral T, Forschner A, Berking C, Gesierich A, Gutzmer R, et al. Conference contribution A patterns of care analysis of hyperthermia in combination with radio(chemo)therapy or chemotherapy in European clinical centers (2022) Ademaj A, Veltsista PD, Marder D, Haelg RA, Puric E, Brunner TB, Crezee H, et al. Journal article Characteristics of people with epilepsy in three Eastern African countries - a pooled analysis (2022) Stelzle D, Kaducu J, Schmidt V, Welte T, Ngowi BJ, Matuja W, Escheu G, et al. Journal article